• We are catalysts for innovation, commercialising next-generation technologies developed by

    The University of Manchester’s world-class research base

    • £360m+ invested by venture funders

    • 40+ spin-out companies created

    • 7,500+ licences and IP partnerships concluded

    • 4,000+ invention disclosures received

    • £115m+ IP and R&D revenue generated for the University

  • We are catalysts for innovation, commercialising next-generation technologies developed by The University of Manchester’s world-class research base

    • £300m+ invested by venture funders since 2004

    • 40+ spin-out companies created

    • 4,800+

      licences and IP partnerships concluded

    • 3,700+ invention disclosures received

    • 1,300+ jobs generated across various industry sectors

    • £105m+ IP and R&D revenue generated for the University

Archive for February, 2011

The Low Carbon and Environment Competition 2011

UMIC and UMIP are delighted to launch The Low Carbon and Environment Competition 2011 and now welcome competition entries for innovative low carbon projects.

If you have an innovative idea for a new low carbon technology, service or behavioural change then we want to hear from you.

The idea does not need to be overtly technology based or a commercial idea. We want to discover as broad a range of ideas as possible.
The competition will be held over a series of heats:

• Heat 1: 7th February to 11th March 2011
• Heat 2: 14th March to 15th April 2011
• Heat 3: 18th April to 20th May 2011

The competition is open to The University of Manchester academics or staff members only.

Up to £5K of commercialisation support from UMIP
Business mentoring and accommodation support package from UMIC
UK patent application preparation and filing from Appleyard Lees
Bespoke marketing and communications solutions from Frontier PR
Entry to a Winning Business Academy course from Winning Pitch
Visit www.umicinnovationportal.co.uk to apply and to find out more about the competition

UMIP appoint Emergo Group as Regulators-in-Residence

UMIP, The University of Manchester’s IP commercialisation company, has appointed Emergo Group, a leading medical device consultancy, as Regulators-in-Residence. Emergo Group will provide regulatory support in relation to the development and commercialisation of University research projects related to medical devices and diagnostics.

The University of Manchester has an extensive track record in biomedical innovation and over the past 18 months, Emergo Group has been involved in providing regulatory input for a number of projects connected to UMIP, and in one case has provided a formal regulatory opinion concerning an in-vitro diagnostic test kit intended to screen women at risk of developing cervical cancer.

Emergo Group senior consultant, Richard Love, will provide regulatory input via quarterly clinics with UMIP’s biomedical staff. Input would include medical device identification and classification as well as the key Regulatory and Quality Management System (QMS) requirements in primary markets such as the EU, USA, Canada and Australia.

Richard commented, “We are delighted to be associated with UMIP and this collaboration presents an exciting opportunity for Emergo Group. We look forward to working with UMIP staff and to providing key regulatory support and guidance as these early stage device and IVD projects evolve into commercial enterprises. More than 90% of our clients are small to medium size companies so we understand their needs and challenges very well.”

Dr Rich Ferrie, Head of UMIP Biomedica, said that he was delighted that Emergo Group had agreed to accept the appointment. “We are very much looking forward to working with Richard and the Emergo Group team. Their extensive expertise will add significant value in shaping the regulatory landscape for our early-stage device and diagnostics technologies and will offer us a clearer vision of the requirements to take our technologies and products to market.”


Manchester businesses in the Life Science sector are promoting their success on the European stage to encourage further investment in the City Region area.

A group of journalists from across Europe visited Manchester as part of an initiative to sell Manchester as an investment destination of choice.

The visit was organised by UK Trade and Investment to showcase the Life Science sector and allow Manchester businesses to promote their expertise.

Journalists from Portugal, Austria, Norway, France and Switzerland took part in the visit on Wednesday 2 February.

UKTI Regional Director Clive Drinkwater said:

“This visit will give us the opportunity to showcase the excellent work taking place in Manchester to the whole of Europe. Manchester hosts some of the most exceptional and truly innovative life science companies in Europe, that are at the forefront of pharmaceutical research and development and pioneering technology helping to improve the quality of people’s lives.

By showing the group of journalists this work we are able to shout about our success across Europe and attract further investment into the country to help our economy to grow.”

The visit has been organised with the help of the Manchester’s Investment and Development Agency (MIDAS) which acts on behalf of the 10 Greater Manchester local authorities to attract inward investment into the City Region.

Angie Robinson, Chief Executive at MIDAS, said:

“Manchester represents a large proportion of the regional life science and biomedical sector within England’s Northwest. The visit is an excellent opportunity to showcase the groundbreaking work taking place in our region to the rest of Europe, cementing Manchester’s position as a major European hub for life sciences activity.”

During the visit the journalists visited:

QIAGEN Manchester Ltd, a Centre of Excellence for Companion Diagnostics. QIAGEN is a personalised medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients.

Renovo, the world leader in scar prevention and reduction research develops pharmaceutical products to prevent and reduce scarring in the skin, blood vessels, eyes, nerves, internal organs, tendons and ligaments. Juvista, Renovo’s lead drug for the improvement of skin scarring following surgery is in the final stages of development with a large Phase 3 trial scheduled to report data in H1 2011. Renovo started out as a venture capital based biotechnology spin-out company from The University of Manchester.

Trimega Laboratories, which opened its Manchester facility in April 2010, is a leading hair alcohol and drug testing company. The company’s hair alcohol testing methods can detect patterns of alcohol consumption over a period of many months as opposed to more traditional methods which only register consumption that has taken place within the space of just a few days. The laboratory was the first in the world to test hair samples of HIV and TB sufferers to see if they have been taking anti-retroviral drugs. Trimega is acknowledged as ‘World Leading’ by the Society of Hair Testing.

Intertek ASG, part of the Global Intertek Laboratory Network, is a specialist Contract Research Organisation (CRO) providing a broad range of advanced scientific and regulatory analysis services to customers involved in the development and manufacture of pharmaceuticals, biopharmaceuticals, medical devices, materials and fine and specialty chemicals.

Manchester Biosciences Incubator and Core Technology Facility, a state-of-the-art biotechnology research and development centre combining the latest in laboratory facilities with an excellent support infrastructure provided by The University of Manchester Incubator Company Ltd. This combination of an exceptional building resource with a commercially and academically supportive incubation environment offers a unique package for biotech start-ups, R&D satellites from pharmaceutical companies and biotech service companies.

Arvia Technology and Magnox Ltd scoop major environmental award

North West based water and waste treatment specialists Arvia Technology Ltd, and Nuclear operators Magnox Ltd, scooped a prestigious Rushlight clean technology award on Thursday 27th January, at one of the UK and Ireland’s premier environmental events.

The companies jointly walked away with the coveted Rushlight Clean Environment Award, in recognition of their partnership in developing the Arvia Titan, a new and highly innovative solution for the treatment of radioactive oil waste. Retrieving and processing this type of waste material is a major challenge, as part of decommissioning and cleaning-up the UK’s nuclear legacy.
Held in Westminster, London, the Rushlight Awards recognise those sustainable businesses that are making a positive difference to the environment through innovation and technological advancement.
Arvia Technology, a spin-out from the University of Manchester, developed new low carbon, waste and chemical free technology for the treatment of water and waste water. However, innovative collaboration with nuclear specialists Magnox Ltd revealed a new and high-value, sustainable solution.
A full scale Arvia Titan unit is now in operation at the decommissioning Trawsfynydd Site in North Wales, providing a sustainable onsite alternative to the incineration of oil waste at specialist facilities across Europe.
Arvia Technology CEO Martin Keighley comments: “This is a very exciting moment for both Arvia Technology and Magnox. Recognition in the UK Cleantech sector doesn’t come any bigger than the Rushlight Awards, and to win the Clean Environment Award is particularly satisfying due to the high volume and quality of entrants this year.
“The Arvia Titan has the potential to not only save on resources and reduce environmental impact – but to also improve safety and efficiency. Put simply, it offers the nuclear sector an entirely new solution – a game changer.”
Trawsfynydd’s Site Director, Dave Wilson, said: “The award is testament to the hard work, inspiration and innovation demonstrated by the project team. Radioactive waste oil is amongst the most difficult waste streams we have to manage at Trawsfynydd – the Arvia solution could prove to be a significant step forward for the whole nuclear industry.”
The awards were hosted by Sir John Beddington, UK Government’s Chief Scientific Advisor.